Close
Help





JOURNAL

Clinical Medicine Insights: Oncology

Bevacizumab for the Treatment of Glioblastoma

Submit a Paper


Clinical Medicine Insights: Oncology 2013:7 123-135

Review

Published on 06 Jun 2013

DOI: 10.4137/CMO.S8503


Further metadata provided in PDF



Sign up for Email Alerts and keep in touch with Clinical Medicine Insights: Oncology journal news, updates, events and articles

Abstract

Glioblastoma (GBM) or grade IV glioma is the most common primary brain tumor in adults. Standard treatment median overall survival (OS) is only 14–15 months and less than 10% of patients will survive 5 years after diagnosis. There is no standard treatment in recurrent GBM and OS ranges from 3 to 9 months. GBM is 1 of the most vascularized human tumors and GBM cells produce vascular endothelial growth factor (VEGF). Bevacizumab, a humanized monoclonal antibody against VEGF, has demonstrated activity in vitro and in phase II trials in relapse, as well as in 1 phase III trial as first line therapy. Bevacizumab also improves quality of life for patients suffering GBM. This paper reviews the mechanism of action of bevacizumab, its metabolism and pharmacokinetic profile. It summarizes the clinical studies in recurrent and newly diagnosed GBM, its potential side effects and complications and its place in therapy.


Downloads

PDF  (602.93 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML




What Your Colleagues Say About Clinical Medicine Insights: Oncology
testimonial_image
My experience publishing in 'Clinical Medicine Insights: Oncology' was excellent.  I was impressed with the quick review and proof-read processes.  The electronic submission website is user friendly, and the continuous manuscript status updates received from the journal were helpful in tracking the progress of the paper.
Dr Tallal Younis (Dalhousie Unversity, Halifax, Nova Scotia, Canada)
More Testimonials

Quick Links


New article and journal news notification services